Use of etanercept in the treatment of dermatomyositis: A case series

Journal of Rheumatology

Volumn 33, Issue 9, 2006, Pages 1802-1804

  Iannone, Florenzo ^a   Scioscia, Crescenzio ^a   Falappone, Paola C F ^a   Covelli, Michele ^a   Lapadula, Giovanni ^a,b,c  

^a UNIVERSITY OF BARI   (Italy)

^b Rheumatology Unit   (Italy)

^c DIMIMP   (Italy)

Author keywords

Anti tumor necrosis factor ; Dermatomyositis; Etanercept

Indexed keywords

ANTIBODY; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; MUSCLE ENZYME; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MUSCLE WEAKNESS; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MUSCLE WEAKNESS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 33748582304     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
2. Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 1998;41:392-9.
3. Lundberg IE, Dastmalchi M. Possible pathogenic mechanisms in inflammatory myopathies. Rheum Dis Clin North Am 2002;28:799-822.
4. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308 A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-77.
5. Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E. Refractory polymyositis responding to infliximab: extended follow-up. Rheumatology Oxford 2004;43:531-2.
6. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-5.
7. Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology Oxford 2004;43:524-6.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
9. Moxley RT, III. Evaluation of neuromuscular function in inflammatory myopathy. Rheum Dis Clin North Am 1994;20:827-43.
10. Miller ML, Smith RL, Abbott KA, Sinacore JM, Pachman LM. Use of etanercept in chronic juvenile dermatomyositis [abstract]. Arthritis Rheum 2002;46 Suppl 9:S306.